iEdgeDTA: integrated edge information and 1D graph convolutional neural networks for binding affinity prediction

20 February 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Drug repurposing, where an existing low-risk drug is applied for new indications, becomes more attractive in drug development as drug discovery is very costly and time-consuming. However, the wet-lab testing process to find a drug candidate for a new purpose from its possible binding to a protein is still expensive and laborious due to the available vast quantity of drugs and target proteins. This study aims to leverage artificial intelligence to aid drug repurposing by utilizing drug-protein interaction data and estimating their binding affinity. In this work, we propose an estimation approach that employs a graph-based deep learning technique and enhances prediction accuracy by incorporating the compound's edge information as a multi-dimensional feature. In addition, we used a pre-trained model for protein embedding and graph operation over a 1D protein sequence to overcome a fixed-length problem in the language model task and also incorporated the global feature of the protein. We evaluated the performance of our model in the same benchmark datasets using a variety of matrices, and the results show that our model can achieve the best prediction result compared to other state-of-the-art models while at the same time requiring no contact-map information compared to recent graph-based works Availability: https://github.com/cucpbioinfo/iEdgeDTA

Keywords

Binding affinity prediction
Graph neural network
Drug repurposing
Deep learning

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.